Acute Ischemic Stroke (AIS)

Acute ischemic stroke (AIS) is characterized by high incidence rate, high mortality rate, high disability rate, high recurrence rate, and high medical cost.

Acute stroke is defined as new-onset neurological dysfunction caused by confined necrosis or softening of brain tissue as a result of acute localized cerebral blood circulation disorders, ischemia, and hypoxia, with signs/symptoms lasting more than 24 hours and CT/MRI excluding cerebral hemorrhage.

It is also the world's second leading cause of death and disability. According to the 2018 Global Burden of Disease report, the overall lifetime risk of stroke in the Chinese population is 39.3%, the highest in the world.

In China, AIS, the most common type of stroke, accounts for approximately 70% of strokes, with a one-year case-fatality rate of 15% and a disability rate of 33.5%, imposing a significant socioeconomic burden on the country.

JX10(formerly BIIB131) is an investigational drug for AIS. Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.

 

Reference:

  • Chinese Expert Consensus on Assessment and Intervention of Collateral Circulation in Acute Ischemic Stroke in Emergency Medicine

  • Guidelines and Consensus | Expert Consensus on Anesthesia Management for Endovascular Treatment of Acute Ischemic Stroke (2020 Edition)